Authors

29 A Demonstration of Opportunity Cost in Surgical Delays When Using Needle Localization Versus MOLLI Localization in Breast Surgery

Compared with wire-guided needle localization, MOLLI localization was associated with shorter median OR delays, fewer overall delays, and an estimated combined annual opportunity cost benefit of nearly $673,000.

78 Liquid Biopsy Insights: Genomic Drivers of Endocrine Resistance in Breast Cancer

ctDNA-based next-generation sequencing in 236 patients with advanced breast cancer revealed frequent PIK3CA, TP53, and ESR1 mutations, highlighting key mechanisms of endocrine resistance with implications for targeted therapy selection.

84 Exceptional Responders in De Novo Metastatic Breast Cancer (dnMBC) Drug Cessation in Patients With HER2-Positive Metastatic Breast Cancer; Multicenter Retrospective Study

Extended drug cessation appears feasible in exceptional responders with HER2+ de novo metastatic breast cancer, with significantly better survival compared with non-exceptional responders.

Unusual Clinical Presentation of Clear Cell Sarcoma in a Young Woman

A young woman presents with painless lumps to the emergency department and is later diagnosed with clear cell carcinoma.

Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer

Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.

16 Magseed Versus Wire Localisation: A Comparison

39 Predictors of Delay in Time From Diagnostic Breast Imaging to Needle Core Biopsy

In 1153 women undergoing breast imaging and NCB, BIRADS 5 status, symptomatic presentation, and age over 70 years were associated with shorter time to biopsy, while socioeconomic and demographic factors were not significant predictors of delay.

84 Exceptional Responders in De Novo Metastatic Breast Cancer (dnMBC) Drug Cessation in Patients With HER2-Positive Metastatic Breast Cancer; Multicenter Retrospective Study

Extended drug cessation appears feasible in exceptional responders with HER2+ de novo metastatic breast cancer, with significantly better survival compared with non-exceptional responders.

18 Advanced Oncoplastic Breast Surgery Using Multiple Pedicles Following Breast-Conserving Surgery: Oncologic and Surgical Outcomes

Advanced oncoplastic breast surgery using multiple pedicles for complex defect reconstruction demonstrated oncologic safety and acceptable complication rates in selected patients undergoing breast-conserving surgery.

58 An Evidence-Based Self-Management Planner for Patients With Metastatic Triple-Negative Breast Cancer: A Multi-Channel Dissemination Initiative

A theory-driven paper planner combined with a digital AI companion demonstrated high acceptability and improved treatment confidence among patients with metastatic TNBC initiating ADC therapy.

45 Use of Preoperative Ultra-Hypofractionated Radiotherapy in Patients With Locally Advanced Breast Cancer: Clinical and Pathological Outcomes

In this single-center retrospective series of 45 patients with locally advanced breast cancer, preoperative 5-fraction ultra-hypofractionated radiotherapy yielded favorable clinical response in 46.6% and clinical downstaging in 92.9% of evaluable surgical cases.

Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer

Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.

Minimal Residual Disease–Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US

Ibrahim Halil Sahin, MD, and colleagues, explore, the CIRCULATE-US (NRG-GI008; NCT05174169) investigating postoperative ctDNA dynamics in early-stage colon cancer for treatment selection.

40 An AI Digital Twin Compares Favorably to Radiologists for Landmark Identification and Measurement in Early-Stage Breast Cancer: A Retrospective, Multi-Institution Clinical Study

In a retrospective multi-institution study of 267 early-stage breast cancer patients, the TumorSight Viz AI algorithm achieved landmark identification and measurement accuracy comparable to inter-radiologist variability, generating results in an average of 8 minutes per patient.

Unusual Initial Presentation of Hepatocellular Carcinoma as a Clavicular Head Mass

Rohit Gupta, MD, et al review a case study of a 70-year-old man who presented with a head mass, and the final diagnosis was hepatocellular carcinoma.

51 The Race, Staging, and Clinical Correlations With Genetic Mutations Diagnosed in Breast Cancer Patients of Multiethnicity Background

Minimal Residual Disease–Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US

Ibrahim Halil Sahin, MD, and colleagues, explore, the CIRCULATE-US (NRG-GI008; NCT05174169) investigating postoperative ctDNA dynamics in early-stage colon cancer for treatment selection.

36 Are Positive Margins in DCIS a True Indication of Inadequate Surgery?

Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.

20 On the Upswing: A Retrospective Cohort Study Evaluating Neoadjuvant Chemotherapy Response in Metaplastic Breast Cancer Patients

In 21 patients with metaplastic breast cancer receiving neoadjuvant chemotherapy, 48% achieved pCR—higher than prior estimates—with all pCR patients alive and disease-free at follow-up, suggesting modern regimens including pembrolizumab may improve outcomes in this chemoresistant subtype.

31 E-Strain Elastography as an Adjunct of Breast Ultrasound: Impact on Biopsy Decision-Making

In 161 biopsied breast masses, malignant lesions showed significantly higher E-strain ratios than benign lesions (3.51 vs 1.93), with progressive increases across BI-RADS categories, supporting elastography as an adjunct to biopsy decision-making.

44 Long-Term Oncological Outcomes After Oncoplastic Therapeutic Mammoplasty With Contralateral Symmetrisation for Early Breast Cancer: A Thirteen-Year Single-Centre Cohort Study

Therapeutic mammoplasty with contralateral symmetrization showed low long-term local recurrence in early breast cancer, with failure to complete adjuvant therapy as the strongest modifiable predictor of recurrence.